Sanofi Wins Appeal Against Mylan Over Oncology Drug Patent

Viatris, formerly Mylan, lost its appeals court bid to invalidate a Sanofi patent on the prostate cancer drug Jevtana.

• The U.S. Court of Appeals for the Federal Circuit, without issuing a formal opinion, affirmed a Patent Trial and Appeal Board decision that let Sanofi amend the claims of patent 8,927,592 to avoid invalidity arguments raised by Mylan
• The board had previously invalidated the patent but was ordered by the court in 2019 to consider Sanofi amendments
• Patent expires in 2031: FDA Orange Book
• Docket link

To contact the reporter on this story:
Susan Decker in Washington at sdecker1@bloomberg.net

To ...